Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 13 Show results per page	View Search Criteria \| Help With Results

Last Modified: 8/10/2006


1.		Phase I/II Study of Fluorouracil, Phenylbutyrate, Indomethacin, and Interferon Gamma in Patients With Advanced Colorectal Adenocarcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				18 and over				NCI				MTS-96322-ME NCI-T96-0015O, NCT00002796, T96-0015

Last Modified: 10/1/2002 First Published: 7/1/2000


2.		Phase II Pilot Study of Phenylbutyrate Plus Azacytidine in Patients With Acute Myeloid Leukemia, Myelodysplasia, Non-Hodgkin's Lymphoma, Multiple Myeloma, Non-Small Cell Lung Cancer, or Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				NCI				MSKCC-99060 NCI-T99-0091, NCT00006019, T99-0091

Last Modified: 12/7/2007 First Published: 9/1/2000


3.		Phase II Study of Phenylbutyrate in Pediatric Patients With Progressive or Recurrent CNS Malignancy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				2 to 21				NCI				TCCC-H-6321 TCCC-GCRC-0692, NCI-O1-C-0028, NCI-T98-0042, NCT00006238, T98-0042

Last Modified: 6/1/1998


4.		Phase I Study of Twice-Daily Intravenous Phenylbutyrate for Advanced Cancer (Summary Last Modified 06/98)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Completed				over 18				NCI				MSKCC-94111 NCI-T94-0170D, T94-0170

Last Modified: 5/1/1999


5.		Phase I Study of Phenylbutyrate as a 120-Hour Infusion in Refractory Solid Tumors (Summary Last Modified 05/1999)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Completed				18 and over				NCI				JHOC-9502 NCI-T94-0097D, T94-0097

Last Modified: 10/1/1999


6.		Phase I Study of Phenylbutyrate for Myelodysplastic Syndrome and Relapsed Acute Myeloid Leukemia (Summary Last Modified 10/1999)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Completed				over 18				NCI				JHOC-9446 NCI-T94-0196D, T94-0196

Last Modified: 7/1/1999


7.		Phase I Study of Phenylbutyrate in Children with Refractory Malignancies (Summary Last Modified 07/1999)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Closed				2 to 21				NCI				TCCC-T96-0044 NCI-T96-0044O, T96-0044

Last Modified: 5/2/2007


8.		Phase I and Pharmacokinetic Study of Phenylbutyrate in Pediatric Patients With Refractory Cancer (Summary Last Modified 01/2001)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Completed				2-21				NCI				NCI-97-C-0051G BCM-H5292, NCI-T96-0044

Last Modified: 4/1/2000 First Published: 1/1/1999


9.		Phase I Study of Phenylbutyrate Plus Tretinoin in Patients With Acute Promyelocytic Leukemia, Neuroblastoma, Non-Small Cell Lung Cancer, or Prostate Cancer (Summary Last Modified 04/2000)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Completed				Not specified				NCI				MSKCC-98081 NCI-T98-0043, T98-0043

Last Modified: 5/9/2006 First Published: 3/1/2000


10.		Phase I Study of Azacitidine in Combination With Phenylbutyrate in Patients With Recurrent, Refractory, or Untreated Acute Myeloid Leukemia or Myelodysplastic Syndrome

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Completed				18 and over				NCI				JHOC-99072307 NCI-T99-0092, NCT00004871, T99-0092, JHOC-J9950

Select All on One Page


					1 2 Next >

| | | | | | | |

A Service of the National Cancer Institute